The study presents a cost‑sensitive XGBoost model that predicts ESBL‑producing Enterobacteriaceae at the time of culture ordering using 45 pre‑culture EHR features from 132,955 cultures across 12 hospitals. At 90% sensitivity the model achieves a 95.8% negative predictive value, potentially allowing carbapenem‑sparing therapy in non‑ICU settings while avoiding unnecessary broad‑spectrum treatment for 307 out of every 1,000 cultures, at the expense of 14 missed ESBL cases per 1,000. SHAP analysis highlights prior ESBL colonization as the strongest predictor, with minimal performance loss when socioeconomic deprivation features are omitted, supporting equitable bedside deployment.
By Aravind V. Kuruvikkattil, Lalitha Pranathi Pulavarthy, Rashmita Kudamala, Saptarshi Purkayastha
arXiv:2609.21332v1 Announce Type: new
Abstract: Acute infectious diseases are among the leading causes of medical consultations and hospitalizations in children worldwide. These infections are predom...
By Mihaela Demireva, Zhecho Mitev, Djuna Chinareva-Klimentova, Svetoslav Ivanov, Georgi Nalbantov, Dimitar Mitev
arXiv:2605.22611v2 Announce Type: replace
Abstract: Antimicrobial stewardship (AMS) is critical in pediatric intensive care units (PICUs), where diagnostic uncertainty often drives broad-spectrum ant...
By Niklas Raehse, Luregn J. Schlapbach, Daphn\'e Chopard
arXiv:2602. 22673v2 Announce Type: replace Abstract: Background: Antimicrobial resistance (AMR) is a global health threat.
By Md Tanvir Hasan Turja
arXiv:2607. 22984v1 Announce Type: cross Abstract: Machine learning models for clinical prediction tasks, such as in-hospital mortality and sepsis onset, routinely achieve high AUROC scores.
By Jie JW Wu, Feiyu E, Bo Chen
This systematic review and meta‑analysis examined 48 machine‑learning studies that predict live‑birth outcomes after IVF/ICSI using routine clinical data. The pooled discrimination of internally validated models was an AUC of 0.814, while externally validated models had an AUC of 0.756, with no significant difference between them. Most studies (47/48) were at high or unclear risk of bias, only four assessed calibration, and none demonstrated clinical impact, leading to a low‑to‑very‑low certainty of evidence.
By Abdul Raheem Shahzad, Muhammad Zaheer Khan, Umar Ajaib, Asad Ur Rehman, Juan Deng, Ming Zhang
arXiv:2605. 12895v2 Announce Type: replace-cross Abstract: Clinical decision-support systems are expert systems whose recommendations clinicians act on directly, yet they are usually cleared on one aggregate accuracy number from a held-out test set.
By Rohith Reddy Bellibatlu, Manpreet Singh, Yash Jajoo, Shyamal Lakhanpal, Abhishek Israni
arXiv:2606. 26179v1 Announce Type: cross Abstract: While WGS-based AMR prediction has reached high accuracy, existing models lack a mechanism to ground neural attributions in established biological pathways.
By Naman Garg, Sarika Jain, Sourav Yadav, Bharat K. Bhargava, Ghanapriya Singh, Abhishek Srivastava, Parimal Kar
arXiv:2509.23552v2 Announce Type: replace-cross
Abstract: Antimicrobial Resistance (AMR) is a rapidly escalating global health crisis. While genomic sequencing enables rapid prediction of resistance...
By Md. Saiful Bari Siddiqui, Nowshin Tarannum
arXiv:2505. 16941v4 Announce Type: replace-cross Abstract: Foundation models (FMs) promise to address core limitations of traditional supervised machine learning: (i) reliance on large amounts of labeled data, (ii) task specificity, and (iii) poor transportability.
By Vincent Jeanselme, Zilin Jing, Aparajita Kashyap, Chao Pang, Florent Pollet, Young Sang Choi, Xinzhuo Jiang, Yuta Kobayashi, Yanwei Li, Sara Matijevic, Karthik Natarajan, Shalmali Joshi
arXiv:2501. 16388v3 Announce Type: replace Abstract: Background: Chronic kidney disease (CKD), a progressive disease with high morbidity and mortality, has become a significant global public health problem.
By Jingying Ma, Jinwei Wang, Lanlan Lu, Zhiqin Jiang, Mengling Feng, Feifei Zhang, Peng Shen, Yexiang Sun, Shenda Hong, Luxia Zhang
arXiv:2608. 07609v1 Announce Type: cross Abstract: High-throughput screening (HTS) assays are central to early-stage drug discovery but are often limited by extreme data sparsity, as primary screens typically use only a single replicate per test substance.
By Xiaohua Douglas Zhang